Autolus Therapeutics (NASDAQ:AUTL) Shares Gap Up to $4.86

Autolus Therapeutics plc (NASDAQ:AUTL) shares gapped up prior to trading on Wednesday . The stock had previously closed at $4.86, but opened at $5.10. Autolus Therapeutics shares last traded at $4.88, with a volume of 43,610 shares trading hands.

Analysts Set New Price Targets

Several research firms have issued reports on AUTL. Truist Financial lifted their target price on Autolus Therapeutics from $10.00 to $11.00 and gave the company a “buy” rating in a research note on Tuesday, April 9th. Needham & Company LLC restated a “buy” rating and set a $9.00 price target on shares of Autolus Therapeutics in a research note on Friday, April 12th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $8.16.

Autolus Therapeutics Price Performance

The stock has a market cap of $1.28 billion, a price-to-earnings ratio of -4.03 and a beta of 1.90. The company’s fifty day moving average price is $5.93 and its 200-day moving average price is $5.08.

Autolus Therapeutics (NASDAQ:AUTL) last posted its quarterly earnings data on Thursday, March 14th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.18). On average, sell-side analysts forecast that Autolus Therapeutics plc will post -0.71 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Autolus Therapeutics

A number of large investors have recently bought and sold shares of the company. UBS Group AG boosted its position in Autolus Therapeutics by 2.8% in the fourth quarter. UBS Group AG now owns 84,655 shares of the company’s stock valued at $545,000 after buying an additional 2,345 shares during the last quarter. BNP Paribas Financial Markets boosted its position in Autolus Therapeutics by 337.3% in the fourth quarter. BNP Paribas Financial Markets now owns 4,268 shares of the company’s stock valued at $27,000 after buying an additional 3,292 shares during the last quarter. Cetera Investment Advisers boosted its position in Autolus Therapeutics by 2.9% in the first quarter. Cetera Investment Advisers now owns 141,600 shares of the company’s stock valued at $261,000 after buying an additional 4,000 shares during the last quarter. EWA LLC boosted its position in Autolus Therapeutics by 40.2% in the fourth quarter. EWA LLC now owns 25,678 shares of the company’s stock valued at $155,000 after buying an additional 7,361 shares during the last quarter. Finally, LPL Financial LLC boosted its position in Autolus Therapeutics by 39.2% in the fourth quarter. LPL Financial LLC now owns 32,300 shares of the company’s stock valued at $61,000 after buying an additional 9,100 shares during the last quarter. Hedge funds and other institutional investors own 72.83% of the company’s stock.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.